{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055698","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.439958+00:00","generated_at":"2026-06-28T10:45:39.130843+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec","bullets":["Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.","Operating loss $23.5M in Q3 2021 vs $12.4M in Q3 2020; R&D expenses rose to $19.3M.","BDC-1001 Phase 1/2 monotherapy interim data (>50 patients) to be presented at ESMO I-O Congress in Dec 2021.","Combination dose escalation with Opdivo expected to start Q4 2021; collaboration with Innovent for up to 3 ISACs.","Cash expected to fund operations through end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055698","json":"https://secwatch.observer/filing/0001564590-21-055698.json","markdown":"https://secwatch.observer/filing/0001564590-21-055698.md","text":"https://secwatch.observer/filing/0001564590-21-055698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021055698/0001564590-21-055698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021055698/bolt-8k_20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:45:39.130843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}